<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Biotherapy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Biotherapy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский биотерапевтический журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9784</issn><issn publication-format="electronic">1726-9792</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">843</article-id><article-id pub-id-type="doi">10.17650/1726-9784-2016-15-4-85-88</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL REPORTS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">CYPHETRYLIN CYTOTOXIC ANALOGUES (REPORT I)</article-title><trans-title-group xml:lang="ru"><trans-title>ЦИТОТОКСИЧЕСКИЕ АНАЛОГИ ЦИФЕТРИЛИНА (СООБЩЕНИЕ I)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Osipov</surname><given-names>V. N.</given-names></name><name xml:lang="ru"><surname>Осипов</surname><given-names>Василий Николаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>ovn65@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Sushinina</surname><given-names>L. P.</given-names></name><name xml:lang="ru"><surname>Сушинина</surname><given-names>Л. П.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ustinkina</surname><given-names>S. V.</given-names></name><name xml:lang="ru"><surname>Устинкина</surname><given-names>С. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Smirnova</surname><given-names>L. I.</given-names></name><name xml:lang="ru"><surname>Смирнова</surname><given-names>Л. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Shprakh</surname><given-names>Z. S.</given-names></name><name xml:lang="ru"><surname>Шпрах</surname><given-names>З. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff id="aff1"><institution>ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России</institution></aff><pub-date date-type="pub" iso-8601-date="2016-12-30" publication-format="electronic"><day>30</day><month>12</month><year>2016</year></pub-date><volume>15</volume><issue>4</issue><fpage>85</fpage><lpage>88</lpage><history><date date-type="received" iso-8601-date="2018-04-10"><day>10</day><month>04</month><year>2018</year></date></history><permissions/><self-uri xlink:href="https://bioterapevt.abvpress.ru/jour/article/view/843">https://bioterapevt.abvpress.ru/jour/article/view/843</self-uri><abstract xml:lang="en"><p>Background. The drug cyphetrylin, hypothalamic hormone somatostatin analogue, was developed in N.N. Blokhin Russian Cancer Research Center at the Ministry of Health of Russia. The basis of this work is the idea of using cyphetrylin as a specific carrier of cytotoxic groups. Objective. Synthesis of cytotoxic cyphetrylin analogues in order to study the effect of the presence of cytotoxic agents on its antitumor activity. Results. The classical methods of peptide chemistry were used for 5 the new cyphetrylin analogues synthesis. The compounds have been obtained by the addition to the cyphetrylin Na-group of the cysteine or lysine Ns-group chlorophenacyl or hydrolyzed сyphelin (cytotoxic agent). Purification of the peptides was performed by column chromatography on silica gel. The purity of the obtained compounds was confirmed by elemental analysis, TLC, optical rotation angle data and HPLC. Preliminary studies of anti-tumor activity were performed in mice transplanted tumors: adenocarcinoma Ca755 breast and melanoma B16. Conclusions. New peptides - analogues cyphetrylin containing cytotoxic fragment have been synthesized, their structure and purity have been confirmed.</p></abstract><trans-abstract xml:lang="ru"><p/></trans-abstract><kwd-group xml:lang="ru"><kwd>аналог соматостатина</kwd><kwd>противоопухолевая активность</kwd><kwd>синтетический пептид</kwd><kwd>somatostatin analogue</kwd><kwd>antitumor activity</kwd><kwd>synthetic peptide</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Смирнова Л.И., Устинкина С.В., Смирнова А.П. и др. Средство, обладающее противоопухолевым действием. Патент РФ № 2254139.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Schally A.V., Comary-Schally A.M., Nagy A. et al. Hypotalamic hormones and cancer. Front Neuroendocrinol 2001;22:248-91. DOI: 10.1006/frne. 2001.0217. PMID: 11587553.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Susini C., Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Annals of Oncology 2006;17(12):1733-42. DOI: 10.1093/annonc/mdl105. PMID: 16801334.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Балаев А.Н., Осипов В.Н., Хачатрян Д.С. Синтетические пептидные аналоги соматостатина: стратегии синтеза и перспективы поиска новых противоопухолевых препаратов. Химико-фармацевтический журнал 2015;49(6):3-9.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Балаев А.Н., Осипов В.Н., Федоров В.Е. и др. Синтез и изучение цитотоксической активности аналогов гипоталамического гормона соматостатина. Российский биотерапевтический журнал 2012;11(4):47-53.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Балаев А.Н., Осипов В.Н., Федоров В.Е. и др. Влияние синтетических пептидных агонистов соматостатина на рост перевиваемых опухолей мышей. Российский биотерапевтический журнал 2013;12(3):57-60.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Кубасова И.Ю., Борисова Л.М., Киселева М.П. и др. Поиск потенциальных противоопухолевых соединений среди аналогов гипоталамического гормона соматостатина. Российский биотерапевтический журнал 2006;3:123-7.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Шпрах З.С., Ярцева И.В., Игнатьева Е.В. и др. Синтез и химико-фармацевтические характеристики аналога соматостатина, обладающего противоопухолевой активностью. Химико-фармацевтический журнал 2014;48(3):19-22.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Smirnova L.I., Smirnova A. P., Ustinkina S.V. et al. Synthesis and antitumor activity of modified somatostatin analogues. Flegel M., Fridkin M., Gilon C., Slaninona J. (Ed.) Peptides 2004 Proceedings of the Third International and Twenty-Eighth European Peptide Symposium, September 5-10. Prague, Czech Republic, 2004. P. 946-947.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Смирнова Л.И., Смирнова З.С., Устинкина С.В. Синтез и противоопухолевая активность гормона гипоталамуса меланостатина и его аналогов. Экспериментальная онкология на рубеже веков. Под ред. М.И. Давыдова, А.Ю. Барышникова. М., 2003. С. 261-280.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Nagy A., Schally A.V. Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombensin to cancer expressing their receptors: a “smarter” chemotherapy. Current Pharmaceutical Design 2005;11(9):1167-80. PMID: 15853664.</mixed-citation></ref></ref-list></back></article>
